Subject's already prescribed drug

Phase 1Small molecule

Subject's already prescribed drug is one of 9 small molecule programs targeting Cicatricial Alopecia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cicatricial AlopeciaActive, not recruiting

Cicatricial AlopeciaPhase 1

Active, not recruiting

Competition

Competitive Landscape

12 competitors in Cicatricial Alopecia

#DrugCompanyPhaseTrials

Rogaine

Pfizer

Approved

1 2

Otezla

Amgen

Approved

1 3

Opzelura

Pfizer

Approved

—4

Kenalog

BBausch Health Americas, Inc.

Approved

1 5

Anzupgo

Alnylam Pharmaceuticals

PF-06651600

1 7

PF-06700841

Pfizer

Phase 2

1 8

Calcipotriol

LEO Pharma

Phase 1

1 9

Subject's already prescribed drug

WWake Forest University Health Sciences

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cicatricial Alopecia1 trial

Calcipotriol as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA)

Withdrawn·WWake Forest University Health Sciences·Phase 1·NCT05416320

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Subject's already prescribed drug. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Subject's already prescribed drug compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Subject's already prescribed drug. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Wake Forest University Health Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: WWake Forest University Health Sciences

Subject's already prescribed drug

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cicatricial Alopecia1 trial

References

Drug Info

Quick Facts

Related News